Boston, MA 07/16/2013 (wallstreetpr) – Ascendiant Capital Markets provided coverage in the shares of the Synthetic Biologics Inc (NYSEMKT:SYN) on a research note issued for investors on Tuesday. The report said that Synthetic Biologics was in collaboration with Intrexon Corporation, the company’s last venture, with the CEO Randal J Kirk. The vision with which Intrexon has been moving forward was to reduce the time, cost and risk which have been associated with the new bio industrial technologies that were to be used by Synthetic Biologics. Making use of the Intrexon propriety technologies, Synthetic Biologics is developing a gamut of monoclonal antibody for the treatment of serious contagious infectious diseases. The company has two monoclonal antibodies being prepared in the pre clinical stage. These two mAb are focused on curing the Acinetobacter and Pertussis infections.
The share price of the company rose 1.18% on Tuesday, reaching $1.77. Synthetic Biologics is also known as Adeona Pharmaceuticals, a biotech company which focuses on the production of synthetic deoxyribonucleic acid for treating serious illnesses.
CFO of Synthetic Biologics Inc (NYSEMKT:SYN) to attend OneMedForum in NYC
It has been reported that the CFO of Synthetic Biologics Inc (NYSEMKT:SYN), John Monahan, shall be present in the 6th Annual meet for the OneMedForum NYC conference on 27th June at the New York Metropolitan Club. Mr. Riley, along with C. Evan Ballantyne and the CFO, shall sit to have a one to one conversation with the investors and analysts who will attend the meeting and have registered for the conference. The live webcast shall be aired.
After the meeting, the archived one will be shown for 30 days from the conference at the Synthetic Biologics website www.syntheticbiologics.com.
